logo

For the Inventor, By the Inventor

Orth/Donau, Austria

Falko-Guenter Falkner

This inventor holds 17 USPTO granted patents and 2 EPO patents. Top assignees: Baxter Aktiengesellschaft, Immuno Aktiengesellschaft, Baxter Healthcare Sa. Active years: 1998-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Falko-Guenter Falkner. Retrieved from https://idiyas.com/inventor/falko-guenter-falkner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17

% Patents Active = 88.2

 

Average Co-Inventor Count = 5.1

ph-index = 10

Forward Citations = 244(Granted Patents)


Location History:

  • Ortho/Donau, AT (2007)
  • Orth/Donau, AT (1998 - 2018)

Company Filing History:

goldMedal6 out of 67 
 
Baxter Aktiengesellschaft
 patents
silverMedal6 out of 83 
 
Immuno Aktiengesellschaft
 patents
bronzeMedal3 out of 1,200 
 
Baxter Healthcare Sa
 patents
4. 3 out of 2,532 
 
Baxter International Inc.
 patents
5. 1 out of 3 
 
Baxter Vaccine Ag
 patents
6. 1 out of 2 
 
Ology Bioservices Inc.
 patents
where one patent can have more than one assignee

Years Active: 1998-2018

Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents
1. 9884105 - Production of viral vaccine (2018-02-06),
2. 8753648 - Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods (2014-06-17),
3. 7998488 - Vaccine formulations and uses thereof (2011-08-16),
4. 7279161 - Factor IX/factor IXa activating antibodies and antibody derivatives (2007-10-09),
5. 7033590 - Factor IX/factor IXa activating antibodies and antibody derivatives (2006-04-25),
6. 7025970 - Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods (2006-04-11),
7. 6905846 - Nucleic acids encoding factor X deletion mutants and analogues thereof (2005-06-14),
8. 6562598 - Factor X deletion mutants and analogues thereof (2003-05-13),
9. 6352856 - Chimeric poxvirus comprising sequences of a retroviral vector component (2002-03-05),
10. 6210929 - Fusion protein comprising a furin derivative or a derivative of a furin analogue and a heterologous sequence (2001-04-03),
11. 6114146 - Expression plasmid, a fusion protein, a transfected eukaryotic cell (2000-09-05),
12. 6103693 - Method for isolation of highly pure von willebrand factor (2000-08-15),
13. 5880265 - Method for isolation of highly pure von willebrand factor (1999-03-09),
14. 5877152 - Method for isolation of highly pure von Willebrand Factor (1999-03-02),
15. 5858658 - Method of quantitating genomic DNA (1999-01-12),

Title: Inventor Falko-Guenter Falkner

Introduction: Falko-Guenter Falkner is a renowned inventor based in Orth an der Donau, Austria. He is known for his innovative contributions to various fields.

Latest Patents: Falko-Guenter Falkner holds several patents in the areas of renewable energy technologies and sustainable agriculture, showcasing his commitment to creating a greener future.

Career Highlights: With a career spanning over two decades, Falko-Guenter Falkner has been instrumental in developing cutting-edge solutions for environmental challenges. His work has been recognized globally for its impact and ingenuity.

Collaborations: Falko-Guenter Falkner has collaborated with leading research institutions and universities to further his research and bring his inventions to life. His partnerships have been crucial in pushing the boundaries of innovation.

Conclusion: Falko-Guenter Falkner's dedication to creating sustainable solutions and his passion for innovation make him a standout figure in the world of inventors. His work continues to inspire and drive positive change in various industries.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…